https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/dr-wendy-heywood-awarded-investigator-initiated-research-proposal-shire-pharmaceuticals/
Dr Wendy Heywood awarded investigator initiated research proposal from Shire Pharmaceuticals
28 Jun 2016, 2:01 p.m.
Following NIHR Great Ormond Street BRC support, which led to the creation of a high-throughput targeted proteomic urine test, Dr Wendy Heywood has been awarded an industry investigator initiated award from Shire Pharmaceuticals.
This award is for a Great Ormond Street Hospital (GOSH) research nurse to facilitate the clinical sample collection pipeline and manage a database of patient samples and clinical information. This Rare Disease Sample Collection will allow researchers at the UCL Institute of Child Health (ICH) and clinicians from the GOSH Metabolic disease clinic, to find new biomarkers, new disease mechanisms, design new treatments and test patients.
This streamlined ICH-GOSH collaboration will enable translation of current and future new metabolic disease biomarkers to clinical laboratories for use in future clinical trials of existing and novel therapies.
Celebrating research that transforms lives
The 2025 NIHR GOSH BRC Showcase recently celebrated some incredible progress made in paediatric research.
GOSH contributes to landmark UAE-UK paper on AI in healthcare
We're proud to have contributed to a new paper published by the UAE-UK Business Council, exploring future opportunities for collaboration in artificial intelligence (AI) in healthcare between the United Kingdom and the United Arab Emirates.
Landmark gene therapy study shows safety for children
Results from the largest cohort of children who received a gene therapy for a rare immunodeficiency condition have shown the long-term safety and efficacy of the curative treatment.
New study pinpoints why some transplanted kidneys are rejected
Researchers at University College London (UCL), the Wellcome Sanger Institute and the University of Cambridge combined technology that determines the genetic or RNA sequence of individual cells with powerful 3D imaging to look at lymphatic vessels